<DOC>
	<DOCNO>NCT00838435</DOCNO>
	<brief_summary>This multicenter , open label study design evaluate safety Kuvan® effect neurocognitive function , blood Phe concentration , growth child PKU 0-6 year old .</brief_summary>
	<brief_title>Effect Kuvan Neurocognitive Function , Blood Phenylalanine Level , Safety , Pharmacokinetics Children With PKU</brief_title>
	<detailed_description>Rigorous control diet typically advocated child 4 year PKU brain sensitivity high Phe concentration expect great year rapid neurocognitive development . Prolonged high blood Phe concentration neurotoxic lead impairment intelligence brain function ( attentiveness ) . Reduction blood Phe concentration dietary control important determinant long-term neurologic outcome PKU patient , reduction blood Phe concentration patient PKU show decrease long term risk neurologic injury . It difficult many patient maintain reduced blood Phe , many patient PKU experience degree neurological impairment despite effort maintain dietary Phe control . The strong determinant intelligence quotient ( IQ ) cognitive function compliance blood Phe control . Several clinical study Kuvan already demonstrate efficacy reduce blood Phe subject old 4 year . This study examine whether addition Kuvan standard care early age child well control diet low blood Phe level ( ie , reach maintain goal ≤ 240 micromole/L ) preserve neurocognitive functioning . In addition , study provide data Kuvan exposure , rate uptake , half life , clearance young child .</detailed_description>
	<mesh_term>Phenylketonurias</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Established diagnosis PKU hyperphenylalaninemia ( HPA ) document medical record least 2 blood Phe concentration great equal 360 micromole/L ( 6 mg/dL ) take least 3 day apart Documented blood Phe control ( defined standard use treatment center ) prior study enrollment , applicable ( eg , subject old enough data collect ) ; blood Phe concentration subject &lt; 6 month old Screening must consider control stable Investigator Willing adhere prescribe Phe restrict diet order maintain blood Phe concentration within recommended range establish subject 's study site Age 0 6 year old , inclusive , Screening Parent ( ) guardian ( ) willing able provide write , sign informed consent nature study explain , prior researchrelated procedure Parent ( ) guardian ( ) willing able comply study procedure Female subject childbearing potential ( determined investigator ) sexually mature male subject willing use medically accept method contraception throughout study . Female subject childbearing potential willing undergo periodic pregnancy test course study Established diagnosis primary tetrahydrobiopterin ( BH4 ) deficiency Known hypersensitivity Kuvan excipients History organ transplantation Perceived unreliable unavailable study participation parent legal guardian perceive unreliable unavailable Use methotrexate medication inhibit folate metabolism Serious neuropsychiatric illness ( eg , major depression ) currently medical control Use Kuvan investigational agent within 30 day prior Screening , know requirement investigational agent prior completion schedule study assessment Concurrent disease condition would interfere study participation safety ( eg , seizure disorder , oral steroiddependent asthma condition require oral parenteral corticosteroid administration , insulin dependent diabetes ) Any condition , view Principal Investigator ( PI ) , render subject high risk failure comply treatment complete study Use phosphodiesterase type 5 inhibitor , often shortend PDE5 inhibitor ( eg , sildenafil citrate , vardenafil , tadalafil , avanafil , lodenafil , mirodenafil , udenafil )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Phenylketonuria</keyword>
	<keyword>PKU</keyword>
	<keyword>Kuvan</keyword>
	<keyword>Phenoptin</keyword>
	<keyword>Biopten</keyword>
	<keyword>Neurocognitive Function</keyword>
	<keyword>Phenylalanine</keyword>
</DOC>